Answers are grounded in this paper and cite their sources.
Conventional risks explain inflammatory marker links to LV function post-transplant; leaves open independent inflammatory effects on cardiac outcomes.
Introduction Cardiovascular disease, including heart failure, is one of the leading causes of morbidity and mortality among liver transplant recipients. Inflammatory markers are associated with heart failure in the general population. We aimed to assess whether high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, and soluble (s)CD163 were associated with left ventricular (LV) systolic function in liver transplant recipients. Methods In this cross-sectional study adult liver transplant recipients from the Danish Comorbidity in Liver Transplant Recipients (DACOLT) study who underwent research transthoracic echocardiography and measurements of hs-CRP, IL-6, and sCD163 were included. Outcomes were LV global longitudinal strain (LV GLS), LV ejection fraction (LVEF), and LV systolic dysfunction, defined as LV GLS <16% and/or LVEF <50%. Results We included 317 participants. Median LV GLS was 18.4% (IQR: 16.4-20.1), median LVEF was 54.0% (IQR: 50.0-57.0), and the prevalence of LV systolic dysfunction was 31.5%. In unadjusted analyses, each doubling of hs-CRP, IL-6, and sCD163 were associated with lower LV GLS with associations of -0.29% (95% CI: [-0.50; -0.08], p=0.008), -0.38% (95% CI: [-0.63; -0.13], p=0.003), and -0.37% (95% CI: [-0.73; -0.02], p=0.041), respectively. Associations with LVEF in unadjusted analyses were -0.61% (95% CI: [-1.02; -0.20], p=0.004), -0.86% (95% CI: [-1.34; -0.38], p=0.001), and -0.37% (95% CI: [-1.07;0.33], p=0.297) per doubling of hs-CRP, IL-6 and sCD163, respectively. However, in models adjusting for sex, age, BMI, and smoking status these associations were attenuated. Conclusion Higher levels of the circulating inflammatory markers hs-CRP, IL-6, and sCD163 were associated with LV systolic function in liver transplant recipients. However, these associations were attenuated in adjusted analyses and thus seem to be explained by traditional cardiovascular risk factors. Prospective studies are needed to determine whether inflammatory markers can improve risk stratification and identify those at increased risk of LV systolic dysfunction and heart failure. Clinical trial registration ClinicalTrials.gov , identifier NCT04777032.
No takes yet. Share an insight, caveat, or question.
Øland et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: